Literature DB >> 36087219

METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma.

Jingyao Hu1, Liang Yang2, Xueqiang Peng2, Minghuan Mao3, Xiaodan Liu4, Jianbo Song5, Hangyu Li6, Fu Chen7.   

Abstract

Liver is a well-known immunological organ with unique microenvironment. In normal conditions, the rich immune-infiltrating cells cooperate with non-parenchymal cells, such as Kupffer cells (KCs). The presence of liver immunosuppressive microenvironment underlines the importance to dissect this interaction to understand how this cross-talk promotes tumor growth in hepatocellular carcinoma (HCC). Therefore, the aim of the study here was to probe the role of methyltransferase-like 3 (METTL3) in the HCC progression and its effect on the polarization of KCs. KCs showed M2 polarization, and METTL3 was overexpressed in our collected HCC tissues relative to adjacent tissues. METTL3 depletion inhibited the M2 polarization of KCs, thereby reverting the malignant phenotype of HCC cells in vitro and growth and metastasis in vivo. Mechanistically, YTH domain-containing family protein 1 (YTHDF1) bound to RNA-binding protein 14 (RBM14), whereas METTL3 knockdown in KCs cells suppressed RBM14 expression by decreasing N-methyladenosine (m6A) methylation. Overexpression of RBM14 mitigated the anti-tumor effects of sh-METTL3 in vitro and in vivo. It is suggested that the mechanism of sh-METTL3 suppressing the polarization of KCs and the progression of HCC is to regulate the RBM14 expression via YTHDF1-dependent m6A modification.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.

Entities:  

Keywords:  Hepatocellular carcinoma; Kupffer cells; METTL3; RBM14; m6A modification

Mesh:

Substances:

Year:  2022        PMID: 36087219     DOI: 10.1007/s13577-022-00769-3

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  29 in total

Review 1.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

Review 2.  Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.

Authors:  Jan Erik Slotta; Otto Kollmar; Volker Ellenrieder; B Michael Ghadimi; Kia Homayounfar
Journal:  World J Hepatol       Date:  2015-05-28

Review 3.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Authors:  Amit G Singal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-15       Impact factor: 11.382

Review 4.  Reading, writing and erasing mRNA methylation.

Authors:  Sara Zaccara; Ryan J Ries; Samie R Jaffrey
Journal:  Nat Rev Mol Cell Biol       Date:  2019-09-13       Impact factor: 94.444

Review 5.  Mapping the epigenetic modifications of DNA and RNA.

Authors:  Lin-Yong Zhao; Jinghui Song; Yibin Liu; Chun-Xiao Song; Chengqi Yi
Journal:  Protein Cell       Date:  2020-05-22       Impact factor: 14.870

Review 6.  Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma.

Authors:  Enakshi Sivasudhan; Neil Blake; Zhi-Liang Lu; Jia Meng; Rong Rong
Journal:  Front Cell Dev Biol       Date:  2021-04-01

Review 7.  The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis.

Authors:  Mengnuo Chen; Chun-Ming Wong
Journal:  Mol Cancer       Date:  2020-02-28       Impact factor: 27.401

8.  METTL3/METTL14 Transactivation and m6A-Dependent TGF-β1 Translation in Activated Kupffer Cells.

Authors:  Yue Feng; Haibo Dong; Bo Sun; Yun Hu; Yang Yang; Yimin Jia; Longfei Jia; Xiang Zhong; Ruqian Zhao
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.